<DOC>
	<DOCNO>NCT02008006</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety BeEAM ( bendamustine , etoposide , cytarabine melphalan ) regimen prior autologous stem cell transplant first second chemosensitive relapse patient follicular lymphoma ( World Health Organisation ( WHO ) grade 1 , 2 , 3a ) .</brief_summary>
	<brief_title>BENdamustine Elevated Dose Relapsed Follicular Lymphoma Intensification Therapy Transplantation ( BENEFIT )</brief_title>
	<detailed_description>The natural history follicular lymphoma ( FL ) mark multiple relapse . The prognosis FL improve use effective sequential chemotherapy introduction anti-cluster differentiation antigen 20 ( anti-CD20 ) monoclonal antibody . Based multiple phase II , high dose chemotherapy ( HDT ) follow autologous stem cell transplantation ( ASCT ) appear effective treatment relapse FL . At rituximab era , 3-years EFS rate 75 % relapse transplanted patient treat first line therapy FL2000 protocol . Bendamustine combine alkylating antimetabolite activity proven clinical activity relapse first line therapy FL . Carmustine ( BCNU ) , etoposide , cytarabine , melphalan ( BEAM regimen ) one use schedule HDT non hodgkin lymphoma . Regarding good safety profile Bendamustine , Visani et al . propose phase I/II bendamustine day -7 -6 , follow etoposide , cytarabine melphalan similar dose BEAM regimen . The bendamustine maximal dose 200 mg/m² day -7 , -6 . Data engraftment show closed result observe BEAM . None patient experience dose limiting toxicity . In context , investigator propose perform multicentric phase II regimen 200 mg/m² day-7 -6 bendamustine first second relapse FL chemosensitive disease salvage therapy . No FL evaluate Visani et al . study . In addition , investigator observe shortage BCNU last year incline evaluate new schedule HDT .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically confirm follicular lymphoma relapse ( WHO grade 1 , 2 , 3a ) Patients age 18 65 year First second chemosensitive relapse salvage therapy ( rituximabchemotherapy ) base 2007 Cheson et al . international response criterion ( CR PR ) decision BeEAM ( HDT ) ASCT ( autologous stem cell transplantation ) treatment Eligible ASCT Autologous graft minimum number cluster differentiation 34 ( CD34+ ) cell 3.0x106/kg . Autologous transplantation perform hematopoietic stem cell transplantation authorize center . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 2 Minimum life expectancy 3 month Cardiovascular baseline correct QT interval F ( QTcF ) ≤ 450 msec ( male ) 470 msec ( female ) Medications may cause correct QT interval ( QTc ) interval prolongation avoid patient enter trial Normal organ marrow function define : Absolute neutrophil count ≥ 1.5 G/l Platelet count ≥ 100 G/l &gt; 75 G/l bone marrow involve Creatine clearance ≥ 50 ml/min Serum Glutamate Oxaloacetate Transaminase ( SGOT ) Serum Glutamate Pyruvate Transaminase ( SGPT ) ≤ 2.5 x Upper Limit Normal ( ULN ) ≤ 5 x ULN liver metastasis Total bilirubin ≤ 1.5 x ULN Cardiac ejection fraction great 50 % echocardiogram multiple gate acquisition scan ( MUGA scan ) Negative serum pregnancy test woman childbearing potential* Pregnancy test include negative serum pregnancy test ( sensitivity least 25 millInternational Unit ( mIU ) /ml ) Women childbearing potential* men must agree use adequate contraception prior study entry , duration study participation 6 month end treatment Female patient meet least one follow criterion define woman nonchildbearing potential : ≥ 50 year old naturally amenorrheic ≥ 1 year Permanent premature ovarian failure confirm specialist gynecologist Previous bilateral oophorectomy XY genotype , Turner 's syndrome uterine agenesis Female patient meet least criterion define woman childbearing potential Ability understand willingness sign write informed consent document Covered medical insurance Signed inform consent EXCLUSION CRITERIA : Transformed follicular lymphoma Prior autologous allogeneic transplantation Presence none chemosensitive disease HDT accord 2007 Cheson et al . international response criterion ( stable progressive disease ) Contraindication drug contain chemotherapy regimen Bone marrow infiltration &gt; 25 % HDT+ASCT Positive HIV , Hepatitis C Virus ( HCV ) Hepatitis B ( HBs ) Ag serologies Current bacterial , viral fungal infection Treatment investigational drug within 30 day enrolment Major surgery within 30 day enrolment Participation another clinical trial within 30 day prior enrolment study study Any serious active disease comorbid medical condition would interfere therapy Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 5 year Known suspected hypersensitivity agent excipients regime evaluation Concomitant treatment chemotherapy immunotherapy radiotherapy Yellow fever vaccination ( attenuated virus vaccine ) Pregnant lactate female Abnormalities cardiac function clinically significant heart disease acute myocardial infarction unstable angina within 6 month prior start study treatment , heart failure New York Heart Association ( NYHA ) class III IV , uncontrolled hypertension history antihypertensive treatment poor compliance , uncontrolled arrhythmia treatment , except extrasystole minor conduction disorder Known involvement central nervous system lymphoma History chronic liver disease History hepatic venoocclusive disease ( VOD ) sinusoidal obstruction syndrome ( SOS ) Excessive alcohol use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Chemosensitive relapse</keyword>
	<keyword>High Dose Chemotherapy</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>BeEAM</keyword>
	<keyword>Autologous Stem Cell Transplantation</keyword>
	<keyword>Safety</keyword>
	<keyword>Event Free Survival</keyword>
	<keyword>Overall Response Rate</keyword>
	<keyword>Progression Free Survival</keyword>
	<keyword>Overall Survival</keyword>
	<keyword>Phase II</keyword>
	<keyword>World Health Organization ( WHO ) 1 grade</keyword>
	<keyword>WHO 2 grade</keyword>
	<keyword>WHO 3a grade</keyword>
</DOC>